Circulating levels of Nɛ-(carboxymethyl)lysine are increased in systemic sclerosis

OBJECTIVE Advanced glycation endproducts (AGEs), including Nepsilon-(carboxymethyl)lysine-protein adducts (CML) are involved in micro/macrovascular changes and are co-localized with adhesion molecules in inflamed tissues. Serum levels of CML were investigated in systemic sclerosis (SSc) characterized by microvascular modifications and correlated with indices of micro/macrovascular damage. METHODS In 66 SSc patients (limited SSc, n = 55; diffuse SSc, n = 11) and 20 controls, CML serum levels were measured by enzyme-linked immunosorbent assay. Nailfold capillaroscopy, intima-media thickness (IMT) and the ankle-brachial index (ABI) were also recorded, to characterize micro/macrovascular involvement. RESULTS CML levels were significantly higher in SSc (79.2 +/- 39 mg/ml vs 49.6 +/- 26.1 mg/ml, mean +/- s.d.; P<0.01), without significant differences between SSc subsets. CML levels were significantly higher in all capillaroscopic patterns: the 'early' pattern showed higher levels than 'active' and 'late' patterns. IMT was significantly higher in SSc (P<0.01) than in controls, whilst ABI was no different from controls. CONCLUSIONS These data indicate that although both CML formation and macrovascular involvement are increased in SSc, there is no correlation between these two parameters. However, the characteristic early nailfold capillaroscopy changes of SSc are associated with proportionally greater CML formation, suggesting that AGEs are involved in SSc microangiopathy.

[1]  James G Terry,et al.  Carotid intimal-media thickness as a surrogate for cardiovascular disease events in trials of HMG-CoA reductase inhibitors , 2005, Current controlled trials in cardiovascular medicine.

[2]  F. Ingegnoli,et al.  [Raynaud's phenomenon]. , 2011, Reumatismo.

[3]  E. Vicaut,et al.  Mannheim Intima-Media Thickness Consensus , 2004, Cerebrovascular Diseases.

[4]  G. Hankey,et al.  Peripheral arterial disease: prognostic significance and prevention of atherothrombotic complications , 2004, The Medical journal of Australia.

[5]  R. Abbate,et al.  Vascular injury in systemic sclerosis: Angiotensin-converting enzyme insertion/deletion polymorphism , 2004, Current rheumatology reports.

[6]  C. Cesaretti,et al.  Oxidative stress in Systemic Sclerosis , 2004, Molecular and Cellular Biochemistry.

[7]  J. Polak,et al.  Intima-media thickness: a tool for atherosclerosis imaging and event prediction. , 2002, The American journal of cardiology.

[8]  J. Mehta,et al.  Does carotid intima media thickness indicate coronary atherosclerosis? , 2002, Current opinion in cardiology.

[9]  R. de Caterina,et al.  Advanced Glycation End Products Activate Endothelium Through Signal-Transduction Receptor RAGE: A Mechanism for Amplification of Inflammatory Responses , 2002, Circulation.

[10]  H. Vlassara,et al.  Diabetes and advanced glycation endproducts , 2002, Journal of internal medicine.

[11]  Y. Shoenfeld,et al.  Classification of anti-endothelial cell antibodies into antibodies against microvascular and macrovascular endothelial cells: the pathogenic and diagnostic implications. , 2002, Arthritis and rheumatism.

[12]  R. Atkins,et al.  Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE). , 2001, The Journal of clinical investigation.

[13]  A. Herrick,et al.  The emerging problem of oxidative stress and the role of antioxidants in systemic sclerosis. , 2001, Clinical and experimental rheumatology.

[14]  A Sulli,et al.  Nailfold videocapillaroscopy assessment of microvascular damage in systemic sclerosis. , 2000, The Journal of rheumatology.

[15]  K. Kushida,et al.  Comparison of the concentrations of pentosidine in the synovial fluid, serum and urine of patients with rheumatoid arthritis and osteoarthritis. , 1999, Rheumatology.

[16]  E. Schleicher,et al.  N(epsilon)-(carboxymethyl)lysine in atherosclerotic vascular lesions as a marker for local oxidative stress. , 1999, Atherosclerosis.

[17]  A. Schmidt,et al.  Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. , 1999, Circulation research.

[18]  R. Ziegler,et al.  AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept. , 1998, Cardiovascular research.

[19]  R. Bucala,et al.  Tobacco smoke is a source of toxic reactive glycation products. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[20]  Alan W. Stitt,et al.  Elevated AGE-Modified ApoB in Sera of Euglycemic, Normolipidemic Patients with Atherosclerosis: Relationship to Tissue AGEs , 1997, Molecular medicine.

[21]  H. Vlassara,et al.  Standardizing the immunological measurement of advanced glycation endproducts using normal human serum. , 1997, Journal of immunological methods.

[22]  H. Sano,et al.  N (epsilon)-(carboxymethyl)lysine protein adduct is a major immunological epitope in proteins modified with advanced glycation end products of the Maillard reaction. , 1996, Biochemistry.

[23]  J. Baynes,et al.  N epsilon-(carboxymethyl)lysine is a dominant advanced glycation end product (AGE) antigen in tissue proteins. , 1995, Biochemistry.

[24]  C. Black,et al.  Increased susceptibility to oxidation of low-density lipoproteins isolated from patients with systemic sclerosis. , 1995, Arthritis and rheumatism.

[25]  E. Friedman,et al.  Hemoglobin-AGE: a circulating marker of advanced glycosylation. , 1992, Science.

[26]  L. Kuller,et al.  The ratio of ankle and arm arterial pressure as an independent predictor of mortality. , 1991, Atherosclerosis.

[27]  T. Medsger,et al.  Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. , 1988, The Journal of rheumatology.

[28]  J. Purcell,et al.  New method for determination of free amino groups in intact pure proteins: relationship to available lysine. , 1976, Journal - Association of Official Analytical Chemists.

[29]  N Rowell,et al.  Systemic sclerosis. , 1968, British medical journal.